Ann: APAS PharmaQC Commercially Ready - Performance Finalised, page-79

Hi Mike, enjoying your posts.

I think everyone has missed the point over the Trading Pause Announcement/Retraction.
The Strategy Update 27/06/2024 contained only 3 dot points:

1. The strategy itself - blah, blah....
2. Evaluations with 2 new MNC pharmaceuticals to commence Sep 2024 Qtr.*
3. AstraZeneca validation progressing as scheduled.

At an Investor Update, when the whole clean rooms concept started to look viable, Barnes advised the audience that a
target of 4 Global Pharmaceuticals would provide meaningful validation and scale.

Achieved to date:

1. AstraZeneca
2. Thermo Fisher (Patheon)
3. Novacina
4. Unnamed MNC #1*
5. Unnamed MNC #2*

So that's at least 5. 1,2 and 3 were all Price Sensitive, so why not 4 and 5?

GLTAH